Columbia News Updates

The Diabetic Retinopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Retinopathy pipeline products will significantly revolutionize the Diabetic Retinopathy market dynamics.  

DelveInsight’s “Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diabetic Retinopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Diabetic Retinopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Retinopathy Market Insights

Some of the key facts of the Diabetic Retinopathy Market Report: 

• The Diabetic Retinopathy market size was valued at USD 3,148.4 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In March 2024, Valo Health, a US-based health technology company, has completed the recruitment of participants for its Phase II Spectra study of OPL-0401, an oral investigational drug aimed at treating diabetic retinopathy (DR). This randomized, placebo-controlled trial aims to evaluate the therapeutic effects of the medication in individuals with moderately severe or severe non-proliferative DR (NPDR) or mild proliferative DR (PDR).

• According to American Academy of Ophthalmology, Diabetic retinopathy (DR) results from high blood sugar levels, which cause damage to blood vessels in the retina

• According to the latest epidemiological data from theAmerican Academy of Ophthalmology, the global burden of diabetes is 387 million and will increase to 592 million by 2035

• Key Diabetic Retinopathy Companies: Bayer, Perfuse Therapeutics, Inc., Hoffmann-La Roche, Boehringer Ingelheim, RemeGen Co., Ltd., Jaeb Center for Health Research, Novartis, Greater Houston Retina Research, Valo Health, Inc., EyePoint Pharmaceuticals, Inc., AbbVie, 4D Molecular Therapeutics, Kodiak Sciences Inc, Guizhou Bailing Group Pharmaceutical, Hanlim Pharm. Co., Ltd., University of Sydney, Incepta Pharmaceuticals, Unity Biotechnology, Alimera Sciences, and others

• Key Diabetic Retinopathy Therapies: Runcaciguat (BAY1101042), PER-001 Intravitreal Implant, DS Implant Pre-Filled with 100 mg/mL, BI 764524, RC28-E injection, Aflibercept Injection, OPL-0401 Dose 1, EYP-1901, Brolucizumab: RGX-314, 4D-150 IVT, Tarcocimab, Tangningtongluo tablets, Entelon Tab. 50mg, Faricimab, Fenofibrate, Ranibizumab 10mg/ml Injection, Aflibercept, Iluvien, and others

• The Diabetic Retinopathy epidemiology based on gender analyzed the prevalence of Diabetic Retinopathy is slightly higher in males as compared to females

Diabetic Retinopathy Overview

Diabetic retinopathy is a diabetes-related complication that affects the eyes. It occurs when high levels of blood sugar damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. Over time, this damage can lead to vision problems and even blindness if left untreated. Diabetic retinopathy can cause the blood vessels in the retina to leak fluid or bleed, leading to swelling and the formation of scar tissue.

Get a Free sample for the Diabetic Retinopathy Market Report –

https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

Diabetic Retinopathy Market  

The dynamics of the Diabetic Retinopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Diabetic Retinopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Retinopathy Epidemiology Segmentation:

The Diabetic Retinopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Diabetic Retinopathy

• Prevalent Cases of Diabetic Retinopathy by severity

• Gender-specific Prevalence of Diabetic Retinopathy

• Diagnosed Cases of Episodic and Chronic Diabetic Retinopathy

Download the report to understand which factors are driving Diabetic Retinopathy epidemiology trends @ Diabetic Retinopathy Epidemiological Insights

Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Retinopathy market or expected to get launched during the study period. The analysis covers Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Retinopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Diabetic Retinopathy treatment, visit @ Diabetic Retinopathy Medications

Diabetic Retinopathy Therapies and Key Companies

• Runcaciguat (BAY1101042): Bayer

• PER-001 Intravitreal Implant: Perfuse Therapeutics, Inc.

• DS Implant Pre-Filled with 100 mg/mL: Hoffmann-La Roche

• BI 764524: Boehringer Ingelheim

• RC28-E injection: RemeGen Co., Ltd.

• Aflibercept Injection: Greater Houston Retina Research

• OPL-0401 Dose 1: Valo Health, Inc.

• EYP-1901: EyePoint Pharmaceuticals, Inc.

• Brolucizumab: Novartis

• RGX-314: AbbVie

• 4D-150 IVT: 4D Molecular Therapeutics

• Tarcocimab: Kodiak Sciences Inc

• Tangningtongluo tablets: Guizhou Bailing Group Pharmaceutical

• Entelon Tab. 50mg: Hanlim Pharm. Co., Ltd.

• Faricimab: Greater Houston Retina Research

• Fenofibrate: University of Sydney

• Ranibizumab 10mg/ml Injection: Incepta Pharmaceuticals Ltd

• Aflibercept: Unity Biotechnology, Inc.

• Iluvien: Alimera Sciences

Diabetic Retinopathy Market Strengths

• Different possible pathways have been extensively studied which could be responsible for the disease. Therefore a better understanding has been obtained through years of thorough research and development

Diabetic Retinopathy Market Opportunities

• A large patient pool allows companies to make cost effective drugs and realize substantial gains

Scope of the Diabetic Retinopathy Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Diabetic Retinopathy Companies: Bayer, Perfuse Therapeutics, Inc., Hoffmann-La Roche, Boehringer Ingelheim, RemeGen Co., Ltd., Jaeb Center for Health Research, Novartis, Greater Houston Retina Research, Valo Health, Inc., EyePoint Pharmaceuticals, Inc., AbbVie, 4D Molecular Therapeutics, Kodiak Sciences Inc, Guizhou Bailing Group Pharmaceutical, Hanlim Pharm. Co., Ltd., University of Sydney, Incepta Pharmaceuticals, Unity Biotechnology, Alimera Sciences, and others

• Key Diabetic Retinopathy Therapies: Runcaciguat (BAY1101042), PER-001 Intravitreal Implant, DS Implant Pre-Filled with 100 mg/mL, BI 764524, RC28-E injection, Aflibercept Injection, OPL-0401 Dose 1, EYP-1901, Brolucizumab: RGX-314, 4D-150 IVT, Tarcocimab, Tangningtongluo tablets, Entelon Tab. 50mg, Faricimab, Fenofibrate, Ranibizumab 10mg/ml Injection, Aflibercept, Iluvien, and others

• Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies

• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Diabetic Retinopathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Retinopathy Market Access and Reimbursement 

Discover more about therapies set to grab major Diabetic Retinopathy market share @ Diabetic Retinopathy market forecast

Table of Contents 

1. Diabetic Retinopathy Market Report Introduction

2. Executive Summary for Diabetic Retinopathy

3. SWOT analysis of Diabetic Retinopathy

4. Diabetic Retinopathy Patient Share (%) Overview at a Glance

5. Diabetic Retinopathy Market Overview at a Glance

6. Diabetic Retinopathy Disease Background and Overview

7. Diabetic Retinopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Retinopathy 

9. Diabetic Retinopathy Current Treatment and Medical Practices

10. Diabetic Retinopathy Unmet Needs

11. Diabetic Retinopathy Emerging Therapies

12. Diabetic Retinopathy Market Outlook

13. Country-Wise Diabetic Retinopathy Market Analysis (2019–2032)

14. Diabetic Retinopathy Market Access and Reimbursement of Therapies

15. Diabetic Retinopathy Market Drivers

16. Diabetic Retinopathy Market Barriers

17.  Diabetic Retinopathy Appendix

18. Diabetic Retinopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Guarav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/